On Friday, Cullinan Therapeutics Inc (NASDAQ: CGEM) was 1.18% up from the session before settling in for the closing price of $10.14. A 52-week range for CGEM has been $9.50 – $30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -25.00%. When this article was written, the company’s average yearly earnings per share was at 17.66%. With a float of $36.83 million, this company’s outstanding shares have now reached $58.14 million.
Let’s determine the extent of company efficiency that accounts for 85 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cullinan Therapeutics Inc stocks. The insider ownership of Cullinan Therapeutics Inc is 36.76%, while institutional ownership is 77.37%. The most recent insider transaction that took place on Jan 06 ’25, was worth 50,040. In this transaction Chief Scientific Officer of this company sold 4,000 shares at a rate of $12.51, taking the stock ownership to the 95,760 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Officer proposed sale 8,000 for $12.68, making the entire transaction worth $101,440.
Cullinan Therapeutics Inc (CGEM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.66% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
You can see what Cullinan Therapeutics Inc (CGEM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 24.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Looking closely at Cullinan Therapeutics Inc (NASDAQ: CGEM), its last 5-days average volume was 0.61 million, which is a jump from its year-to-date volume of 0.56 million. As of the previous 9 days, the stock’s Stochastic %D was 20.34%. Additionally, its Average True Range was 0.77.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 7.31%, which indicates a significant decrease from 21.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.72% in the past 14 days, which was higher than the 57.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.73, while its 200-day Moving Average is $17.42. However, in the short run, Cullinan Therapeutics Inc’s stock first resistance to watch stands at $10.46. Second resistance stands at $10.67. The third major resistance level sits at $10.81. If the price goes on to break the first support level at $10.11, it is likely to go to the next support level at $9.97. Should the price break the second support level, the third support level stands at $9.76.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
There are 58,228K outstanding shares of the company, which has a market capitalization of 597.42 million. As of now, sales total 0 K while income totals -153,160 K. Its latest quarter income was 0 K while its last quarter net income were -40,560 K.
